Prostate Accurately Targeted Radiotherapy Investigation of Overall Treatment Time

Conditions

Prostatic Neoplasms

Keywords

Radiotherapy, Hypofractionation

Brief summary

The purpose of this study is to compare the toxicity of two new radiation schedules for the treatment of prostate cancer. Patients will be randomized to receive 5 treatments delivered every other day over 11 days, or once per week over 29 days. Both of these schedules are shorter than the standard treatment which is usually 39 treatments over 8 weeks.

Wee Loon Ong, Harvey Quon, Aldrich Ong, Patrick Cheung, William Chu et al. (20 authors)

European Urology Oncology2025-04-26

10.1016/j.euo.2025.03.011

Every-other-day or once-a-week: Long-term efficacy outcomes of the multicenter randomised PATRIOT prostate SBRT trial.

Wee Loon Ong, Harvey Quon, Aldrich Ong, Patrick Cheung, William Chu et al. (20 authors)

Journal of Clinical Oncology2024-01-291 citations

10.1200/jco.2024.42.4_suppl.325

Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL)

Vedang Murthy, Indranil Mallick, Abhilash Gavarraju, Shwetabh Sinha, Rahul Krishnatry et al. (16 authors)

BMJ Open2020-02-0127 citations

10.1136/bmjopen-2019-034623

Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation

Boram Ha, Kwan Ho Cho, Kang Hyun Lee, Jae Young Joung, Yeon-Joo Kim et al. (14 authors)

Radiation Oncology2019-01-1024 citations

10.1186/s13014-019-1210-7

Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.

Quon HC, Ong A, Cheung P, Chu W, Chung HT, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Loblaw A.

2018-03-1553 citations

10.1016/j.radonc.2018.02.029

PATRIOT Trial: Randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time.

Harvey Quon, Aldrich Ong, Patrick Cheung, William Chu, Hans T. Chung et al. (19 authors)

Journal of Clinical Oncology2015-03-0113 citations

10.1200/jco.2015.33.7_suppl.6

Interventions

RADIATIONImage-guided radiotherapy

40 Gy / 5 fractions / 11 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Low or intermediate risk prostate cancer patients as defined by: * Clinical stage T1-2b, Gleason Score \<=7, and PSA \<=20 ng/mL * Age \>= 18 years

Exclusion criteria

* Androgen deprivation therapy (LHRH-agonists or antiandrogens) \>6 months * Prior pelvic radiotherapy * Anticoagulation medication (if unsafe to discontinue for gold seed insertion) * Diagnosis of bleeding diathesis * Large prostate (\>90cm3) on imaging * Immunosuppressive medications * Inflammatory bowel disease

Design outcomes

Primary

Measure	Time frame
Bowel related quality-of-life	3 months

Secondary

Measure	Time frame	Description
Gastrointestinal toxicity	During radiotherapy, at 3 and 6 months, then every 6 months after	Radiation Therapy Oncology Group Acute and Late Morbidity Scoring Schema
Genitourinary toxicity	During radiotherapy, at 3 and 6 months, then every 6 months after	Radiation Therapy Oncology Group Acute and Late Morbidity Scoring Schema
PSA relapse rate	3 and 5 years	—
Patient Overall Quality of life	During radiotherapy, at 3 and 6 months, then every 6 months after	—
Salvage androgen deprivation therapy rate	3 and 5 years	—

Countries

Canada

Outcome results

None listed